Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?
about
Association of toll-interacting protein gene polymorphisms with atopic dermatitisRNA interference of interferon regulatory factor-1 gene expression in THP-1 cell line leads to Toll-like receptor-4 overexpression/activation as well as up-modulation of annexin-IIWnt5a is expressed in murine and human atherosclerotic lesionsGeneration of anti-TLR2 intrabody mediating inhibition of macrophage surface TLR2 expression and TLR2-driven cell activation.The TLR9 gene polymorphisms and the risk of cancer: evidence from a meta-analysisAssociation of toll-like receptor 2 gene polymorphisms with normal tension glaucomaTemporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection.Sleep and inflammation in resilient agingThe association between Toll-like receptor 2 single-nucleotide polymorphisms and hepatocellular carcinoma susceptibilityAdenovirus RIDalphabeta complex inhibits lipopolysaccharide signaling without altering TLR4 cell surface expression.Cognitive behavioral therapy and tai chi reverse cellular and genomic markers of inflammation in late-life insomnia: a randomized controlled trial.Anti-inflammatory effect of patchouli alcohol isolated from Pogostemonis Herba in LPS-stimulated RAW264.7 macrophages.Frequency of TLR 2, 4, and 9 gene polymorphisms in Chinese population and their susceptibility to type 2 diabetes and coronary artery disease.Toll-like receptors in ocular immunity and the immunopathogenesis of inflammatory eye disease.Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosusCharting protein complexes, signaling pathways, and networks in the immune system.Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block.Atherosclerosis: immune and inflammatory aspects.Critical appraisal of the current practice in murine TNBS-induced colitis.Suppression of TLR signaling by targeting TIR domain-containing proteinsToll-like receptors in atherosclerosisMechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets.Why sleep is important for health: a psychoneuroimmunology perspective.Transcriptional regulation of the novel Toll-like receptor Tlr13.Toll gates to periodontal host modulation and vaccine therapySleep loss activates cellular markers of inflammation: sex differences.Complementary Tolls in the periodontium: how periodontal bacteria modify complement and Toll-like receptor responses to prevail in the host.The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.The expression and functions of toll-like receptors in atherosclerosis.Prophylactic and therapeutic implications of toll-like receptor ligands.Toll-like receptors play a crucial part in the pathophysiological activity of antiphospholipid antibodies.Starring role of toll-like receptor-4 activation in the gut-liver axis.Anti-inflammatory activity of hydrosols from Tetragonia tetragonoides in LPS-induced RAW 264.7 cells.Ethanol Extract of Potentilla supina Linne Suppresses LPS-induced Inflammatory Responses through NF-κB and AP-1 Inactivation in Macrophages and in Endotoxic mice.The Role of Toll-Like Receptors in Autoimmune Diseases through Failure of the Self-Recognition Mechanism.Anti-Inflammatory Effect of Apigenin on LPS-Induced Pro-Inflammatory Mediators and AP-1 Factors in Human Lung Epithelial Cells.Sleep Health: Reciprocal Regulation of Sleep and Innate Immunity.Oxyresveratrol suppresses lipopolysaccharide-induced inflammatory responses in murine macrophages.Chikusetsusaponin V inhibits inflammatory responses via NF-κB and MAPK signaling pathways in LPS-induced RAW 264.7 macrophages.In silico analysis and experimental validation of molecular mechanisms of salvianolic acid A-inhibited LPS-stimulated inflammation, in RAW264.7 macrophages.
P2860
Q21256682-8D338C17-1DAD-49DB-B1D6-B5533532F845Q24303890-FA49839D-1359-4EA2-8FC1-057BFC7C8D1EQ28278954-C53E5902-15DD-4246-8920-A8A5E876F53BQ30980638-038CFBCA-5ECA-43B9-BBCD-68EB7C8455E9Q31131769-497E7CE0-120D-46A9-9BC8-6664A08C6B4EQ33574079-F0D6B587-0DDD-4A76-B1BC-A980F4DC2D48Q33984320-004917B6-D071-41C6-BBC0-D421C256527FQ34079367-909B949A-0AC1-4669-9E61-A4FAB3DFCC58Q34151951-098D0697-5EEC-4D2C-AC1D-9ABCCDF7F0A2Q34717215-CB354C4D-27C3-4DA3-98EC-8FAF81AB40D7Q35915869-0C406423-3E83-4DB6-AEE1-23B0F712BB09Q36230620-65C412B8-4A9A-4833-8BFE-9B4A5B63CA99Q36311828-94F04EC6-8655-4183-A1A9-0915DDB6BC32Q36345480-7E7376EC-8FFD-4492-BAD2-B45218C6F2A5Q36403653-7CB8D07D-0874-407B-A188-961BA4F6BC16Q36453373-1CA94242-B937-4437-92CB-2F917D1F8611Q36551073-FF668A22-4F66-48E0-B82D-CD286501FD4CQ36583651-2E6DB043-3B6B-4740-A108-83C5ABD51B34Q36609213-775DE984-3AD8-41E0-8F75-050C13330709Q36676056-3225CA7C-C896-4C99-9DAC-953DF789A083Q37091891-14BCBDE7-31DC-4C3B-935F-226B1342D3B1Q37106639-7D83C0DF-C334-485D-90B0-0E4EBE9F0190Q37127346-88D02247-E775-4208-B87E-255D5DB1925FQ37343959-7F0D467B-1B9A-4412-957A-AA2B1D18C561Q37416211-E284A81D-41F2-4F18-B147-40560C0BCDB4Q37456718-956F7FDD-56ED-4B71-82A6-716DA6F3CF83Q37486358-07CC8079-1F93-4FF2-A897-98262C577FF2Q37530899-45C0BE12-5C62-4D5F-8BF5-E882CAE9F665Q37774869-16F1C324-1E70-4A48-9CEB-B45A8DA21720Q37989884-D48A5157-D616-42FF-B6C8-FFC05DCBB055Q38497394-4BB520DA-79E0-4A21-AF8C-EE7D9552DC5CQ38645789-AEA88B51-6F12-4D90-8C23-BF6D210E9549Q38685189-3F6375FA-C323-4B57-AF29-11A389A25E01Q38719199-D9D73E03-3346-4C2B-BEF1-511A61F4B357Q38758892-75A1831D-179B-4962-815D-869A3B77FC26Q38843639-D090262C-ED69-4002-BBA8-6458B22DB3F9Q38924060-DCC91D46-E0AB-4405-BB25-2AEF98ACDDAFQ38937717-B99F0EE8-5675-40F3-A4CE-F2F9653743DCQ38955920-59C1C156-ED31-4CFF-8080-0F26C29CDF9DQ39096435-E1C9E98D-CAA7-4446-A450-BA4C420ED9C4
P2860
Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Is targeting Toll-like recepto ...... cytokine-driven inflammation?
@ast
Is targeting Toll-like recepto ...... cytokine-driven inflammation?
@en
type
label
Is targeting Toll-like recepto ...... cytokine-driven inflammation?
@ast
Is targeting Toll-like recepto ...... cytokine-driven inflammation?
@en
prefLabel
Is targeting Toll-like recepto ...... cytokine-driven inflammation?
@ast
Is targeting Toll-like recepto ...... cytokine-driven inflammation?
@en
P2093
P2860
P1476
Is targeting Toll-like recepto ...... cytokine-driven inflammation?
@en
P2093
Brian Foxwell
Evangelos Andreakos
Marc Feldmann
P2860
P304
P356
10.1111/J.0105-2896.2004.00202.X
P577
2004-12-01T00:00:00Z